Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety.
暂无分享,去创建一个
[1] S. Suissa,et al. Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study , 2021, COPD.
[2] Yaa-Hui Dong,et al. Comparative Safety and Effectiveness of Inhaled Corticosteroids and Long-Acting β2 Agonist Combinations in Patients with Chronic Obstructive Pulmonary Disease. , 2019, Chest.
[3] S. Suissa,et al. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD , 2019 .
[4] Jessica M Franklin,et al. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners , 2019, BMJ.
[5] S. Suissa,et al. Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. , 2019, Chest.
[6] Darren Lunn,et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum , 2019, International journal of epidemiology.
[7] J. Castellsagué,et al. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD) , 2019, Pharmacoepidemiology and drug safety.
[8] S. Suissa,et al. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. , 2018, The Lancet. Respiratory medicine.
[9] S. Rennard,et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. , 2018, The Lancet. Respiratory medicine.
[10] I. Pavord,et al. Eosinophils in COPD: just another biomarker? , 2017, The Lancet. Respiratory medicine.
[11] K. Rothnie,et al. Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care , 2017, International journal of chronic obstructive pulmonary disease.
[12] S. Suissa,et al. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events , 2017, European Respiratory Journal.
[13] S. Suissa,et al. Prevalent new‐user cohort designs for comparative drug effect studies by time‐conditional propensity scores , 2017, Pharmacoepidemiology and drug safety.
[14] L. Smeeth,et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records , 2016, Clinical epidemiology.
[15] L. Smeeth,et al. Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records , 2016, PloS one.
[16] I. Pavord,et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD , 2015, Thorax.
[17] K. Bhaskaran,et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.
[18] C. Strange,et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study , 2015, Respiratory Research.
[19] L. Smeeth,et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD) , 2014, BMJ Open.
[20] S. Suissa,et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia , 2013, Thorax.
[21] C. Janson,et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study , 2013, Journal of internal medicine.
[22] C. Janson,et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS) , 2013, BMJ.
[23] Brian Sauer,et al. The incident user design in comparative effectiveness research , 2013, Pharmacoepidemiology and drug safety.
[24] Bernadette A. Thomas,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[25] S. Stanojevic,et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.
[26] Joshua P Metlay,et al. Accuracy of pneumonia hospital admissions in a primary care electronic medical record database , 2012, Pharmacoepidemiology and drug safety.
[27] F. Radner,et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. , 2011, American Journal of Respiratory and Critical Care Medicine.
[28] C. Blanchette,et al. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management , 2011, Journal of medical economics.
[29] L. Blais,et al. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication , 2010, Clinical therapeutics.
[30] L. Smeeth,et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review , 2010, British journal of clinical pharmacology.
[31] W. Ray,et al. Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.
[32] Corri Black,et al. Validity of the General Practice Research Database , 2003, Pharmacotherapy.
[33] S. Suissa,et al. Long‐Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events: A Population‐Based Comparative Safety Study , 2017, Chest.
[34] P. Calverley,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.